How Private Credit Is Displacing Bank Debt in Leveraged Buyouts: What It Means for Deal Valuations
<
Why Regulated-Industry Startups Are Capturing Disproportionate Series B Capital in Europe: What the Investment Thesis Actually Requires
TLDR: Regulated-industry startups in healthtech, insurtech, legaltech, and compliance-tech are capturing an...
Read More
Where April 2025 Digital Health Capital Actually Went
April 2025's biggest digital-health cheques went to diagnostics, metabolic hardware, care-operations software, and fertility infrastructure. Where value compounds next.
Read More
Oncology's Data Gold Rush: The Asset Is the Patient Data
In 2025 pharma majors moved from buying AI to building it on someone else's data. Tempus and ConcertAI showed the asset in oncology AI is the patient data.
Read More
Neumarz Market Outlook January 2026
2026 M&A trends: why European and Swiss buyers are targeting US assets, plus outlook on healthcare, financial services, and energy consolidation.
Read More
The 2026 Strategic Horizon: Capital Allocation in an Era of Physical Scarcity and Fiscal Dominance
As the 2023-2025 cycle concludes, market consensus suggests a fundamental regime change. The "high nominal growth" era is giving way to a period defined by shrinking cash yields, physical resource constraints, and aggressive industrial policy.
Read More
Europe’s Big AI Bet: How New Guidelines Will Shape the Future of General-Purpose AI Models
Europe’s Bold Step into AI’s Future Setting Clear Boundaries for AI Innovation...
Read More
European Venture Capital Performance Holds Strong—But for How Long?
Europe’s venture capital stays ahead with rising valuations and dry powder, but liquidity challenges threaten its lead as US exits regain pace.
Read More